The Current State of Hormonal Therapy for Prostate Cancer

  title={The Current State of Hormonal Therapy for Prostate Cancer},
  author={Beth A. Hellerstedt and Kenneth J. Pienta},
  journal={CA: A Cancer Journal for Clinicians},
Androgen deprivation therapy remains a mainstay of treatment for men with prostate cancer. New uses for hormonal therapy, including use in the adjuvant and neoadjuvant setting, are being evaluated. Prevention of the side effects of therapy has led to the development of alternative schedules and therapeutics. 

Novel Androgen Deprivation Therapy (ADT) in the Treatment of Advanced Prostate Cancer.

Hormonotherapy of advanced prostate cancer.

  • P. PronzatoM. Rondini
  • Medicine
    Annals of oncology : official journal of the European Society for Medical Oncology
  • 2005
Androgen ablation remains the mainstay of treatment for advanced stages, while Docetaxel based chemotherapy is becoming the standard in hormonorefractory tumors and targeted therapies are approaching.

The role of radiation therapy in the treatment of metastatic castrate-resistant prostate cancer

A variety of radiotherapeutic options exist for palliation in the setting of castrate-resistant prostate cancer, including both external beam radiotherapy and radiopharmaceuticals, which are focused on in this article.

New pharmacological treatments for prostate cancer

In this article, a summary of new drugs available for patients with prostate cancer, such as degarelix, abiraterone acetate, sipuleucel-T, bone-targeted therapies, and chemotherapeutic agents, and

The truth is out there: an overall perspective on androgen deprivation.

Current Pharmacological Treatment Options for Prostate Cancer

The current pharmacological treatment options in the management of prostate cancer are reviewed to lead to earlier diagnosis and more effective management.

Risk of new‐onset diabetes after androgen deprivation therapy for prostate cancer in the Asian population

The risk of new‐onset diabetes mellitus (DM) after ADT for prostate cancer in the Asian population is investigated to investigate the associations of androgen deprivation therapy with its adverse events.

Survival outcomes in men receiving androgen‐deprivation therapy as primary or salvage treatment for localized or advanced prostate cancer: 20‐year single‐centre experience

To evaluate the overall survival (OS) and disease‐specific survival (DSS) in men receiving primary androgen‐deprivation therapy (PADT) or salvage medical ADT (SADT) for prostate cancer.

Androgen deprivation therapy and estrogen deficiency induced adverse effects in the treatment of prostate cancer

By providing clinicians with a greater awareness of the estrogen deficiency induced adverse effects from ADT, they can proactively intervene on the physical and psychological impact these effects have on patients.

Cryoablative response of prostate cancer cells is influenced by androgen receptor expression

To investigate in prostate cancer cells the consequences of androgen‐insensitivity (AI) development on the cellular and molecular responses to freezing, as a challenge in prostate cancer treatment



Trends in the utilization of androgen‐deprivation therapy for patients with prostate carcinoma suggest an effect on mortality

After a surge in the incidence of prostate carcinoma in the early 1990s, diminishing rates of mortality became apparent in 1993. This decrease in mortality is unlikely to be explained entirely by

Side effects of endocrine treatment and their mechanisms: Castration, antiandrogens, and estrogens

This paper is a survey of the most important early side effects of the different modes of endocrine treatment, their etiology, and possible ways to avoid or treat them.

Why phase III trials of maximal androgen blockade versus castration in M1 prostate cancer rarely show statistically significant differences *

The meta‐analysis of maximal androgen blockade (MAB) concluded that there is no survival advantage of MAB over castration alone. However, the results from the largest trials yield conflicting results.

The effect of combined androgen blockade on bone turnover and bone mineral densities in men treated for prostate carcinoma

The purpose of this study was to evaluate markers of bone turnover and to measure bone mineral densities in men with disseminated prostate carcinoma treated with combined androgen blockade prior to and after 6 months of intermittent cyclic etidronate therapy.

Intermittent Androgen Blockade in Prostate Cancer: Rationale and Clinical Experience

Experimental and preclinical studies concerning intermittent androgen blockade are reviewed and it is found that through the cycling of reversible androgen suppression, there appears to be recovery of apoptosis and subsequent slower progression to an androgen–independent state.

Treatment of localized prostate cancer with intermittent triple androgen blockade: preliminary results in 110 consecutive patients.

Although median follow-up is short, triple androgen blockade therapy followed by finasteride maintenance appears to be a promising alternative for the management of patients with clinically localized or locally advanced prostate cancer.